Cargando…
Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer
PURPOSE: The clinical potential of liquid biopsy in patients with advanced cancer is real-time monitoring for early detection of treatment failure. Our study aimed to investigate the clinical validity of circulating tumor DNA (ctDNA) treatment monitoring in a real-life cohort of patients with advanc...
Autores principales: | Frank, Malene S., Andersen, Christina S.A., Ahlborn, Lise B., Pallisgaard, Niels, Bodtger, Uffe, Gehl, Julie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035379/ https://www.ncbi.nlm.nih.gov/pubmed/36969747 http://dx.doi.org/10.1158/2767-9764.CRC-22-0258 |
Ejemplares similares
-
Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment
por: Frank, Malene Støchkel, et al.
Publicado: (2021) -
Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
por: Spindler, Karen Lise Garm, et al.
Publicado: (2015) -
Using structured progress to measure competence in flexible bronchoscopy
por: Cold, Kristoffer Mazanti, et al.
Publicado: (2020) -
The experience of being a participant in one’s own care at discharge and at home, following a severe acute exacerbation in chronic obstructive pulmonary disease: a longitudinal study
por: Andersen, Ingrid Charlotte, et al.
Publicado: (2017) -
Circulating biomarkers to monitor cancer progression and treatment
por: Rapisuwon, Suthee, et al.
Publicado: (2016)